Health Archive » December, 2011

Health - December, 2011

195 articles

• Doctors Seek High Court Reversal Of DNA Patentability
• Bristol-Myers Escapes Navy Encryption IP Suit
• FDA Warns Of New Baby Acetaminophen Dosage Risks
• Docs' Businesses Can Challenge Medicare Rule: DC Circ.
• Medical Supply Co. Owner Gets 12 Years In Medicaid Fraud
• Santarus Tries To Shoot Down Zydus' Generic Zegerid
• Knocking Out Potential Kickback Relationships
• Canada, EU To Probe Novartis Diabetes Drug
• Hospira Investors Go After Board Over Inflated Stock Prices
• DNA Probe Patent Suit Belongs In California: Fed. Circ.
• HGS Execs Hid Lupus Drug's Suicide Link: Suit
• Judge Drops Revived UnitedHealth Kickback Suit
• Sanofi, Sun Settlement Ends Plavix Patent Case
• Ripe For Comment: The CMS Sunshine Rule
• Black & Decker, Others Sued For Dump Site Cleanup Costs
• J&J Targets 12M Bottles Of Motrin In Latest Recall
• Marine Polymer V. HemCon: New Breed Of Intervening Right
• NY Court Sets Test For Summary Judgment In Bias Cases
• Novartis, Others Can't Stop Generic Tobramycin Suit
• SC AG Can't Skirt AstraZeneca Improper Penalty Claims
• Tris Pharma Kicks Cough Syrup Infringement Claims
• Genentech Sues Dr. Reddy's Over Generic Valcyte
• 5th Circ. Asked Not To Rehear MediQuip Insurance Tiff
• Arbitrator, Not Court, Should Decide Consolidation: 7th Circ.
• Immersion Beats $300M Suit Over Pumped-Up Stock Prices
• French Doctor Gets Time Served For Insider Trading
• Worker's Migraines Can't Carry ADA Claims: 10th Circ.
• House Asks DHS To Fork Over Docs On $433M SIGA Deal
• Olympus Tokyo Offices Raided In Probe Of $2B Fraud
• Judge Won't Nix $327M Verdict Over J&J's Risperdal
• The War On Health Care Fraud: 2011 And Beyond
• Ranbaxy Settles With FDA, Sets Aside $500M For DOJ Probe
• UT Immune From Wrongful Termination Suit: 5th Circ.
• Bard Picks Up Device Maker Lutonix For $325M
• Asthma Center Nurse's ADA Suit Time-Barred: 2nd Circ.
• Harry Connick Jr. Sues Medicare Provider Over Ad Videos
• France Calls For Removal Of 30,000 Breast Implants
• Merck Reaches $24M Deal To End Mass. Medicaid Suit
• NY State Senator Resigns, Cops To Bribe Scheme
• Ex-NFL Player Fronted Heart Device Co. Stock Scam: SEC
• New VC Fund To Invest $75M In Early-Stage Health Cos.
• Pfizer, Sandoz Agree To End Caduet Patent Fight
• Medicare And The Confusion Over Insurer Reporting
• 9th Circ. Remands Calif. Workers' Health Insurance Suit
• Simplyhealth To Buy Axa Dental Unit For $180M
• Judge Trims J&J Investor Suit Over Kids' Meds Recalls
• Smith & Nephew's $85M Win Axed In Suture Anchor IP Row
• SIGA Can't Scrap Smallpox Drug Profit-Share Ruling
• Rejecting Brand-Liability Theory Post-Mensing
• Nursing Home CEO Let Out Of Medicaid FCA Case
• FDA Tightens Restrictions On Sanofi's Multaq
• Supreme Court Sets Arguments In Health Care Fight
• CDI Defenses Slashed In Medicare Kickback Suit
• FCA Recoveries Top $3B For 2nd Year In A Row
• Preparing For HIPAA's New Audit Program
• Pfizer, Others To Shell Out $6M For Superfund Cleanup
• Pfizer Seeks To Stymie Sandoz, Accord's Generic Torisel
• HHS To Let States Set Benefit Benchmarks For Health Plans
• New FDA Rules To Up Women In Medical Device Studies
• Sens. Float Bill To Improve Watch Over Medical Devices
• KV Again Shakes Suit Over Metoprolol Recall
• Scrutinizing Reverse-Payment Settlements
• Even Data Privacy Obligations Are Bigger In Texas
• Calif. Plaintiff Can't Crash NJ Bayer Probiotics Actions
• Shire Takes Aim At Mylan Again In New Intuniv Patent Suit
• Kimberly-Clark Sues Cardinal Over Sterilization Wrap IP
• UCLA Faces $16M Class Action Over Stolen Patient Info
• J&J Unit Aims To Thwart Sandoz's Generic Doribax
• Teva Unit Targets Celgene Breast Cancer Drug In IP Suit
• Shearman Aids Fujifilm In $995M Buy Of Ultrasound Co.
• J&J Unit Hits Covidien With Surgical Tool Patent Suit
• Covidien To Separate $2B Pharmaceuticals Unit
• Cipro Pay-For-Delay Suit Heads To Calif. High Court
• Merck Sells NJ Office Building To PE Venture
• Cancer Institute Says Doctor Stole $1B In Research
• Blue Cross Escapes Class Action Over Hefty Premiums
• JPML Won't Merge 12 Actions Over Plavix Injuries
• Sealing The Deal: Skadden Splits Diabetes Drug Alliance
• Bayer's Off-Label Yaz Marketing Violated FCA: Watchdog
• Widening The Class Certification Circuit Split
• Choate Hall Aids Investment Firms In HealthMEDX Buy
• Olympus Recognizes $1B Loss To Avoid Stock Delisting
• Biotech REIT Scores Boston Lab Complex For $308M
• Watson Pays $27M To Exit Drug Inflation MDL
• DOJ Sets Record-High $6B Fraud Recovery In 2011
• DOJ Seeks To Add $1M To Mass. $13M Cleanup Settlement
• Ironwood Lied To Patent Offices: $500M Suit
• FDA Blasts Medical Centers Over Deceptive Lap-Band Ads
• FDA Ducks Contempt Claim After Nixing OTC Contraceptives
• Warner Chilcott Takes Aim At Lupin's Generic Generess Fe
• Baxter Scoops Up Synovis For $325M
• 4th Exec Jailed For Illicit Human Testing Of Bone Cement
• Sidley Austin Welcomes Greenberg IP Pro To SF Office
• McKool Smith Ousted From CHS Whistleblower Suit
• Shoddy Accounting Put HCA Stock On Life Support: Suit
• Determining Patentability Of Personalized Medicine
• Merck Urges 3rd Circ. To OK Pay-For-Delay Settlements
• Medtronic Investors Win Cert. In Off-Label Marketing Case
• Medtronic Strikes $23.5M Deal In Doctor Kickbacks Dispute
• Gibson Dunn Lures New FDA Practice Leader From Sidley
• Impax's Generic Amrix Must Stay Banned: Cephalon, Mylan
• 11th Circ. Nixes FTC Bid To Halt $195M Ga. Hospital Deal
• Symmetry Picks Up J&J Unit's Surgical Tool Line For $165M
• Pharmacies' Pfizer Merger Appeal Stays Out Of High Court
• Contractor Cops To $1M MFA Kickback Scheme
• Judge Sides With FTC In ProMedica Merger Challenge
• Valeant Cedes Drugs To Win OK For $770M Skin Care Buys
• Fed. Circ. Nixes Injunction On Mylan's Generic Doryx
• Vaccine Purchasers Accuse Sanofi Of Stifling Competition
• Rockford Rerun: The FTC On Hospital Mergers
• SEC Targets Glaxo Unit Over Underpriced Stock Buybacks
• Teva Settles Suit Over Watson's Generic LoSeasonique
• Ex-Shionogi IT Employee Gets 3.5 Years For Hacking
• Valeant Ends Fight With Par Over Generic Antidepressant
• Hospira Misled Investors To Pump Up Stock Prices: Suit
• FTC, Boehringer Wrangle Over Generics Settlement Docs
• Insurer John Alden Escapes Health Coverage Class Action
• Australia To Step Up Regulation Of Homeopathics
• Merck Scores Patent Extension Win In EU High Court
• 6th Circ. Backs Ex-B. Braun Worker In Off-Label Drug Case
• Two Firsts In Post-Mensing Litigation
• Pfizer Settles Menopause Drug Suit After $73M Verdict
• Bayer Should Stress Clot Risk On Yaz Label: FDA Panel
• Calif. AG Seeks Medtronic Bone Graft Docs
• Pfizer Sues Alembic Over Lyrica ANDA
• Novartis, Celgene Hit Teva Again Over ADHD Drug Patents
• UK Pushes Full Exam For $7.8B Private Medical Industry
• LabCorp's $85M Orchid Deal Depends On Divestment: FTC
• Nutter Pulls In Former Pfizer Patent Pro
• Insurer Must Defend BestComp Under E&O Policy: 5th Circ.
• How The Supreme Court Will Tackle Health Care Reform
• Fed. Circ. Affirms Cephalon Win In Generic Fentora IP Suit
• Ernst & Young To Review Olympus Audits Amid Scandal
• Brand's Off-Label Promotion: Valuable Tool For Generics
• Medical Supply Co. Settles False Claims Suit For $5M
• J&J, Coloplast, Others Face Cancer Treatment Patent Suit
• High Court Ponders Limits Of Patentability In Mayo Suit
• Drugmakers Sue Wockhardt Over Tricor ANDA
• Nonprofit Can't Get EEOC's Obesity Suit Thrown Out
• House OKs Bill To Boost Congress' Power Over Regulations
• HealthpointCapital Takes On Surgical Tool Maker Blue Belt
• Humana Picks Up Health Analytics Leader Anvita
• Small Bone Gets $43M In Credit From New Health Capital
• Bayer Battles Generic Yasmin Hopeful In Fed. Circ.
• NC Dental Board Stifled Competition: FTC
• Medline Seeks To Avoid Bill For Surgical Mesh Suits
• Plan B Birth Control Still Requires Prescription, HHS Says
• Lannett Cuts Deal With Celgene In Thalomid Antitrust Case
• Caraco V. Novo Nordisk — A Divided Supreme Court
• Conditions Of Participation And Payment As Qui Tam Defense
• Buying A Distressed Hospital Out Of Bankruptcy
• Pfizer Hit With $73M Verdict In Menopause Drug Suit
• Lupin Must Halt Sales Of Generic Diabetes Drug: Judge
• Express Scripts Exec Defends $29B Merger To Lawmakers
• FDA Eases Risk Mandates For GSK, Amgen Platelet Drugs
• Retirement Community Hurt By Recession Enters Ch. 11
• FDA To Weigh Public Input On Biosimilars Program
• KV Pharma To Shell Out $17M In FCA Settlement
• Shire Patent Suit Dismissal Will Delay Generic: Alkem
• J&J Pays $2M To Exit Idaho AG's Drug Pricing Suit
• Olympus Panel Urges Legal Measures Against 'Rotten' Execs
• Targeting Health Care Execs Under Park Doctrine
• Bayer Covered Up Yasmin Blood Clot Risk: Ex-FDA Head
• GOP Sens. Urge FTC To Probe $29B Express Scripts Merger
• Hospital Can Use Hearsay To Bar Worker's Threats: Court
• Class Attys Get $1.5M In Allstate Cancer Policy Settlement
• Hatch-Waxman Provision Splits High Court In Generics Row
• UK Plan To Share Patient Data With Drug Industry Draws Ire
• Nixon Peabody Wins Over FDA Insider From Reed Smith
• DOL Targets Fraudulent Group Insurance Plans
• VA Unit Skipped Reviews For $1.6B In Contracts: Report
• Argentum Hits Chicago Firm With $5M Suit Over IP Loss
• High Court Won't Weigh FCA's Scope In Blackstone Case
• Roche Scoops Up Verum Diagnostica
• Sanofi Presses Fed. Circ. To Nix Dr. Reddy's Allegra Win
• A Sign Of Future Biosimilars Litigation?
• Lawmakers Press Tricare On SAIC Data Security Policy
• HHS Sets Loss Ratio Rules Capping Insurer Profits
• High Court To Tackle Novo Nordisk's Generic Drug Fight
• Judge Refuses To Lift Ban On Generic Lovenox
• JZ Capital Unloads Stake In Health Services Co.
• Pfizer Can't Shake Birth Defect Suit Over Worker's Child
• PE Firm Great Point Deals Bioscience Co. To Corning
• Mayo Case Could Clarify Patentability, Expand On Bilski
• Stent Wars: Return Of The Lost Patent
• Hagens Berman Off Hook In Ala. Firm's Atty Fee Battle
• Plan For Single EU Patent Moves Ahead
• Spectralytics Adds To $22M IP Verdict Against Cordis
• House Panel Votes To Nix CLASS Health Care Program
• Insurers Settle Scuffle Over $44M Hospital Defect Suit
• The Murky Waters Of Off-Label Liability
• Fed. Circ. Keeps Teva Out Of Luck Over Crestor Patent
• Walgreen, Kroger Join Fray Over Wyeth's Effexor Tactics
• Carlyle Unit Adds French Medical Casting Biz
• Bausch & Lomb Snaps Up Argentinian Contacts Co.